InsidersTradesSigma
Explore the detailed record of transactions filed by Cross John Harry III, 首席财务官. Officer active across 1 company, notably Sonnet BioTherapeutics Holdings, Inc.. In total, 1 reports have been published. Regulator: SEC (Form 4). All data is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
John Harry III Cross is the Chief Financial Officer at Sonnet BioTherapeutics Holdings, Inc. He is responsible for the financial management of the company, including financial planning and performance analysis. His role is crucial for the financial health of the organization.